Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 09, 2009
Impax Laboratories Acquires Rights to Abbreviated New Drug Applications
Dec 03, 2009
Amneal Receives FDA Approval for Nizatidine Oral Solution, The First Generic Oral Solution for Axid® In The Market
PDF format download (opens in new window)
Dec 02, 2009
Impax Laboratories Acquires Rights to Abbreviated New Drug Applications
Nov 24, 2009
Global Pharmaceuticals Awards Grant to Myasthenia Gravis Alliance
Nov 10, 2009
Impax Laboratories to Present at the Credit Suisse 18th Annual Healthcare Conference
Nov 03, 2009
Impax Laboratories Continues Trend of Solid Growth in Revenue, Profit and Earnings for the Third Quarter 2009
Oct 30, 2009
Impax Laboratories Confirms Patent Challenge Relating to TRICOR(R) 48mg and 145mg Tablets
Oct 26, 2009
Impax Pharmaceuticals Initiates Second Phase III Trial of IPX066 in Parkinson's Disease
Oct 13, 2009
Impax Laboratories to Host Third Quarter 2009 Earnings Conference Call and Webcast on November 3
Oct 07, 2009
Impax Laboratories Settles Pending Litigation for FLOMAX(R)
Oct 05, 2009
Impax Laboratories Receives Tentative FDA Approval for Generic FLOMAX(R) 0.4mg Capsules
Oct 01, 2009
Impax Laboratories Commences Shipment of Generic Adderall XR(R) Capsules, 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg
Sep 28, 2009
Impax Laboratories to Present at the JMP Securities Healthcare Focus Conference
Sep 21, 2009
Impax Laboratories Confirms Patent Challenge Relating to ORACEA(R) Delayed-Release Capsules, 40mg
Sep 21, 2009
Impax Pharmaceuticals Reports Positive Results of Phase II Trial of IPX066, a Novel Formulation of Carbidopa-Levodopa for Parkinson’s Disease
Sep 16, 2009
Impax to Present at the UBS Global Life Sciences Conference
Sep 08, 2009
Impax to Present at the Morgan Stanley Global Healthcare Conference
Aug 24, 2009
Impax Laboratories to Ring NASDAQ Opening Bell
Aug 05, 2009
Impax Laboratories Receives Final FDA Approval for Generic Depakote(R) Extended-Release 500mg Tablets
Aug 04, 2009
Impax Laboratories Reports Second Quarter 2009 Financial Results
Jul 13, 2009
Impax to Host Second Quarter 2009 Earnings Conference Call and Webcast on August 4
Jun 15, 2009
Amneal Expands Generic Portfolio With Launch of Alprazolam ER and Benazepril HCI Tablets
PDF format download (opens in new window)
Jun 15, 2009
Impax Laboratories to be Added to Russell 3000(R) Index and NASDAQ Biotechnology Equal Weighted Index
Jun 03, 2009
Impax to Present at Upcoming Investor Conferences
May 19, 2009
Impax Receives FDA Approval for Generic Precose(R) Tablets, 25 mg, 50 mg and 100 mg
May 11, 2009
Impax Laboratories Added to NASDAQ Biotechnology Index
May 09, 2009
Amneal Receives Rare FDA Approval For Extended Phenytoin Sodium Capsules, USP
PDF format download (opens in new window)
May 09, 2009
Amneal Receives FDA Approval For Its Second Liquid Rx Product, Prednisolone Sodium Phosphate, USP
PDF format download (opens in new window)
May 06, 2009
Impax to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference May 13
May 06, 2009
Impax Receives Final FDA Approval for Generic Depakote(R) Extended-Release 250mg Tablets
May 05, 2009
Impax Reports Improved First Quarter 2009 Revenue and Profit
Apr 28, 2009
Impax to Host First Quarter 2009 Earnings Conference Call and Webcast on May 5
Apr 20, 2009
Impax Pharmaceuticals Reports Positive Achievements on its Two Leading Brand Product Candidates IPX066 and IPX056
Apr 06, 2009
Impax Confirms Patent Challenge Relating to Renvela(R) 800 mg Tablets
Mar 20, 2009
Impax Confirms Patent Lawsuit Relating to Doryx(R) Tablets 150 mg
Mar 19, 2009
Impax Pharmaceuticals to Co-Promote Wyeth's Pristiq(R)
Mar 17, 2009
Impax Confirms Patent Challenge Relating to RENAGEL(R) Tablets, 400 mg and 800 mg
Mar 17, 2009
Impax Confirms ANDA Filing for Doryx(R) Tablets 150 mg
Mar 12, 2009
IMPAX Common Stock to Begin Trading on NASDAQ
Mar 12, 2009
Impax to Present at the Cowen and Company 29th Annual Health Care Conference March 18
Mar 09, 2009
Amneal Successfully Completes Technology/Site Transfers For Acebutolol And Flecainide
PDF format download (opens in new window)
Mar 03, 2009
Impax to Present at the Barclays Capital Global Healthcare Conference
Feb 26, 2009
IMPAX Reports Fourth Quarter and Full Year 2008 Financial Results
Feb 24, 2009
IMPAX to Host Fourth Quarter and Full Year 2008 Earnings Conference Call and Webcast on February 26
Feb 05, 2009
IMPAX Receives Final FDA Approval for Generic SOLODYN Extended-Release Tablets, 45mg, 90mg and 135mg
Jan 27, 2009
IMPAX Resolves Remaining SEC Comments on Form 10 Registration Statement
Jan 23, 2009
IMPAX Receives Final FDA Approval for Omeprazole 40 mg Capsules
Jan 21, 2009
IMPAX Laboratories Adopts Shareholder Rights Plan
Jan 15, 2009
Impax Comments On Recent Stock Trading
Jan 08, 2009
Impax Confirms Patent Challenge Relating to Amrix (R) Extended-Release Capsules, 15mg and 30mg
Jan 07, 2009
Impax To Present at the 27th Annual J.P. Morgan Healthcare Conference
Jan 05, 2009
Impax Appoints Christopher Mengler, R. PH., President of Global Pharmaceuticals Division

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top